DMPK Principal Scientist / Associate Director

Genesis Therapeutics is pioneering artificial intelligence guided rational drug design to address severe unmet medical needs for patients. Our lab in San Diego is looking for a motivated and versatile Drug Metabolism and Pharmacokinetics (DMPK) Principal Scientist or Associate Director to join our team to help advance our compounds through preclinical and clinical development. The successful candidate will be driving the overall PKPD modeling and simulation (M&S) effort to support projects from early research through early clinical development.

This is a full-time position in a fast-paced biotech environment with a collegial group of high-level colleagues working towards well-defined goals. Full medical and dental benefits, flexible work hours/vacation included in this opportunity to learn all aspects of biotech start-up.

Learn more about us here:https://www.genesistherapeutics.ai/

And our recent collaboration with Eli Lilly here:

https://endpts.com/genentech-partnered-genesis-therapeutics-inks-newest-ai-discovery-deal-with-eli-lilly/

What you will do:

• Represent DMPK as the technical expert on project teams, providing scientific and strategic leadership for all stages of discovery and early development.
• Design, develop, execute (or manage conduct) and interpret high-throughput and mechanistic ADME assays and data to enable small molecule drug discovery efforts.
• Design, interpret and integrate pharmacokinetic (PK), pharmacokinetic/pharmacodynamic (PK/PD), and ADME data to enable estimation of human pharmacokinetics and human pharmacologically active dose.
• Partner with AI engineer on ADME predictive model
• Preparation of nonclinical DMPK/ADME reports and documents for candidate nomination and regulatory filing.
• Collaborate and communicate across departments to guide understanding of ADME studies and fundamentals to support drug discovery.

What you will bring:

• A Master’s or Ph.D. in Pharmaceutics, Pharmacokinetics, Pharmacology, Biomedical engineering or related discipline with 8+ years Industrial experience in Drug Discovery & Development.
• Expertise in the development on conduct of in vitro and in vivo ADME assays
• Experience in LC/MS/MS bioanalytical method development and application
• Knowledge in the conduct, analysis, and interpretation of in vivo pharmacokinetics and PKPD studies.
• Ability to conduct self-directed research and to work effectively in a dynamic environment with a diverse team of coworkers.
• Solid written and oral communication skills, enthusiasm, integrity, self-motivation, strong interpersonal skills, and attention to detail are necessary.
• Level determined will be commensurate with experience.

What we offer:

• Competitive Pay
• Stock Option Eligibility
• 401(k) Plan
• Open PTO Policy
• Paid Company Holidays
• Free lunch and snacks at our offices
• Health Care Plan, including Medical, Dental, and Vision, fully covered for the employees

About Genesis Therapeutics 

Genesis Therapeutics is a pioneering AI Biotech company focusing on the discovery of novel drugs using unique approaches to both undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases. 

Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. In addition, Genesis has announced two AI platform collaborations across a range of therapeutic areas with Genentech and h Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. We’ve also been featured in Forbes 30u30 and in Forbes AI 50. 

Genesis originated in graph machine learning research in Vijay Pande’s lab at Stanford, when it was joined by legendary drug hunters and biotech entrepreneurs (including Dr. Leonard Bell, founder and CEO of Alexion Pharmaceuticals, acquired by Astra Zeneca for $39Bn; and Peppi Prasit, storied chemist from Merck known for Vioxx, Arcoxia, Singulair, who then went on to found Amira Pharmaceuticals, acquired by BMS, and Inception Sciences). The company is making strong progress in expanding the domain of our AI technology with the advance of our pipeline of best-in-class and first-in-class programs, both internal targets and those in partnership with Genentech and Lilly.